Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Routine surveillance for symptomatic toxicities with real-time clinician reporting in Danish breast cancer patients-Organization and design of the first national, cluster randomized trial using the Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE)

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{9a555e7b9162451f976964d1eb185639,
title = "Routine surveillance for symptomatic toxicities with real-time clinician reporting in Danish breast cancer patients-Organization and design of the first national, cluster randomized trial using the Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE)",
abstract = "The Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE) was developed by the National Cancer Institute to capture patient self-reports of symptomatic toxicities during cancer treatment. The aim of this short communication is to describe the design of a national study, which examine the effect of using patients' electronic PRO-CTCAE reporting with real-time feedback to clinicians on treatment events for breast cancer patients receiving adjuvant chemotherapy. The study's end-points are defined as dose reduction, hospitalization, and febrile neutropenia. This is the first report on the impact of PRO-CTCAE in a national breast cancer population during chemotherapy treatment.",
keywords = "PRO-CTCAE, adjuvant chemotherapy, breast cancer, patient reported outcome, toxicity, Humans, Hospitalization, Neutropenia/chemically induced, Randomized Controlled Trials as Topic, Denmark, Female, Chemotherapy, Adjuvant/adverse effects, Breast Neoplasms/drug therapy, Patient Reported Outcome Measures",
author = "Helle Pappot and Christina Baeksted and Ann Knoop and Mitchell, {Sandra A} and Aase Nissen and Christoffer Johansen",
note = "{\circledC} 2019 Wiley Periodicals, Inc.",
year = "2019",
doi = "10.1111/tbj.13204",
language = "English",
volume = "25",
pages = "269--272",
journal = "Breast",
issn = "0960-9776",
publisher = "Churchill Livingstone",
number = "2",

}

RIS

TY - JOUR

T1 - Routine surveillance for symptomatic toxicities with real-time clinician reporting in Danish breast cancer patients-Organization and design of the first national, cluster randomized trial using the Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE)

AU - Pappot, Helle

AU - Baeksted, Christina

AU - Knoop, Ann

AU - Mitchell, Sandra A

AU - Nissen, Aase

AU - Johansen, Christoffer

N1 - © 2019 Wiley Periodicals, Inc.

PY - 2019

Y1 - 2019

N2 - The Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE) was developed by the National Cancer Institute to capture patient self-reports of symptomatic toxicities during cancer treatment. The aim of this short communication is to describe the design of a national study, which examine the effect of using patients' electronic PRO-CTCAE reporting with real-time feedback to clinicians on treatment events for breast cancer patients receiving adjuvant chemotherapy. The study's end-points are defined as dose reduction, hospitalization, and febrile neutropenia. This is the first report on the impact of PRO-CTCAE in a national breast cancer population during chemotherapy treatment.

AB - The Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE) was developed by the National Cancer Institute to capture patient self-reports of symptomatic toxicities during cancer treatment. The aim of this short communication is to describe the design of a national study, which examine the effect of using patients' electronic PRO-CTCAE reporting with real-time feedback to clinicians on treatment events for breast cancer patients receiving adjuvant chemotherapy. The study's end-points are defined as dose reduction, hospitalization, and febrile neutropenia. This is the first report on the impact of PRO-CTCAE in a national breast cancer population during chemotherapy treatment.

KW - PRO-CTCAE

KW - adjuvant chemotherapy

KW - breast cancer

KW - patient reported outcome

KW - toxicity

KW - Humans

KW - Hospitalization

KW - Neutropenia/chemically induced

KW - Randomized Controlled Trials as Topic

KW - Denmark

KW - Female

KW - Chemotherapy, Adjuvant/adverse effects

KW - Breast Neoplasms/drug therapy

KW - Patient Reported Outcome Measures

U2 - 10.1111/tbj.13204

DO - 10.1111/tbj.13204

M3 - Journal article

VL - 25

SP - 269

EP - 272

JO - Breast

JF - Breast

SN - 0960-9776

IS - 2

ER -

ID: 56584193